Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

Presentation ACC 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presenter: Eric Quinton Klug

April 07, 2024

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Shelley Wood

April 07, 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

Shelley Wood

April 01, 2024

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Caitlin E. Cox

March 14, 2023

News Conference News ACC 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Todd Neale

March 10, 2023

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Shelley Wood

March 04, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Conference News ACC 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

Todd Neale

April 03, 2022

News Conference News ACC 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Yael L. Maxwell

May 16, 2021

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Opinion Editor's Corner ACC 2019

Live From New Orleans: Days 2 and 3 at ACC 2019

Shelley Wood

March 18, 2019

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Shelley Wood

March 11, 2019

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Michael O'Riordan

March 11, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

Advertisement

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

What’s Going to Be Hot at ACC 2024

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Live From New Orleans: Days 2 and 3 at ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content